Core Viewpoint - JiuDian Pharmaceutical has acquired the developed results and corresponding intellectual property of JIJ02 gel from Chengdu Ped Bio-Pharmaceutical Co., Ltd. for 90 million yuan to enrich its product line [2] Summary by Category Company Developments - JiuDian Pharmaceutical announced the acquisition of JIJ02 gel, previously known as "PD-DP-008 gel," to enhance its product offerings [2] Financial Performance - For the year 2024, JiuDian Pharmaceutical's revenue composition is as follows: - Pharmaceutical preparations: 80.43% - Active pharmaceutical ingredients: 7.81% - Pharmaceutical excipients: 6.69% - Plant extracts and others: 3.73% - Technology transfer and services: 1.29% [2]

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) has acquired all developed results and corresponding intellectual property rights of JIJ02 gel from Chengdu Ped Bio-Pharmaceutical Co., Ltd. for 90 million yuan, aiming to enrich its product line [1] Group 1 - The acquisition amount is 90 million yuan [1] - The acquired product is JIJ02 gel, previously known as "PD-DP-008 gel" [1] - A technology transfer contract has been signed between the two companies [1]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于受让取得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步丰富产品线，湖南九典制药股份有限公司（以下简称"公司"）以 9,000 万元受让成都佩德生物医药有限公司（以下简称"成都佩德"）拥有的 JIJ02 凝胶（原申报名称"PD-DP-008 凝胶"）的全部已开发成果及相应知识产权，并 签署了《技术转让合同书》。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。本次交易无需提交董事会和股东会审议。近日，公司与成都 佩德完成了临床批件转让手续。现将有关事项公告如下： 一、临床试验通知书基本情况 药品名称：JIJ02 凝胶（原申报名称"PD-DP-008 凝胶"） 注册分类：化学药品 1 类 受理号：CXHL2401082 拟定适应症：寻常痤疮 审批结论：根据《中华人民共和国 ...

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

格隆汇8月21日｜昂利康、九典制药、康泰生物涨超6%，兴齐眼药涨超5%，君实生物、阳光诺和、荣 昌生物涨超3%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 002940 | 昂利康 | 6.59 | 106亿 | 301.09 | | 300705 | 九典制药 | 6.39 | 101亿 | 14.43 | | 300601 | 康泰生物 | 6.14 | 210亿 | 10.48 | | 300573 | 兴齐眼药 | 5.71 | 167亿 | 38.45 | | 600200 | *ST苏吴 | 5.49 | 6.82亿 | -89.70 | | 002424 | 贵州百灵 | 4.79 | 88.75亿 | 64.94 | | 430047 | 诺思兰德 | 3.94 | 80.25亿 | 153.77 | | 300147 | ST香雪 | 3.81 | 75.65亿 | 17.09 | | 688180 | 君实生物-し | 3.44 | 476亿 | 69.67 | | 688621 | 阳光诺 ...

Core Insights - Liuyang Economic Development Zone has been recognized as one of the "Top Ten Investment-attractive Parks for 2025" in Hunan Province, reflecting its strong investment attraction and business environment [1] - In the first half of the year, the zone's industrial added value grew by 12.7% year-on-year, and fixed asset investment increased by 14.5%, with industrial technology transformation investment surging by 71.1% [1] - The zone successfully introduced 52 projects with a contractual investment amount exceeding 22 billion yuan, achieving over half of its annual target of 100 projects [1] Administrative-driven Policies - The administrative-driven investment strategy relies on "fund leverage" and "policy guidance" to set the tone for project introductions [3] - Policies have been optimized to support the medical device industry, including rewards for companies obtaining product registration and production licenses [3][4] - The zone has introduced measures to support emerging industries and future industries, focusing on project-driven development [4] Market-driven Initiatives - Market-driven investment strategies are led by Jinyang Investment Group, which has established a focus on investment financing, urban operation, and industrial cultivation [6] - The group has partnered with nearly 20 private equity investment institutions, participating in 29 funds with a total scale exceeding 20 billion yuan [7] - The proportion of projects attracted through fund-driven initiatives has increased from 10-20% to 80-90% [7] Business Environment Optimization - The zone emphasizes a collaborative approach to project implementation, ensuring that companies receive comprehensive support upon settling [9][10] - The "simulated approval" process has expedited project timelines, reducing the average construction cycle by 40 days [10] - A "three-person service" model provides dedicated support to each enterprise, enhancing satisfaction rates to 100% [10] Future Outlook - With the acceleration of the 3 billion yuan mother fund and the expansion of reforms like "immediate construction upon land acquisition," the zone is poised for continued success in attracting investments [11]

Group 1 - The company primarily serves domestic clients, with foreign clients representing a smaller business volume [2] - Domestic clients mainly consist of large commercial distribution companies [2]

Core Viewpoint - JiuDian Pharmaceutical (300705.SZ) has provided a positive earnings forecast for 2025, expecting a revenue growth of 10%-20% and a non-net profit growth of 10%-20% [2][4]. Financial Performance - From 2022 to 2024, JiuDian Pharmaceutical's revenue increased approximately 2.2 times, net profit increased about 8.3 times, and non-net profit grew around 9.2 times [2][8]. - In 2024, the company achieved a revenue of 2.931 billion yuan, a year-on-year increase of 8.85%, and a net profit of 512 million yuan, up 39.13% [4]. - For Q1 2025, the company reported a revenue of 696 million yuan, a year-on-year growth of 17.79%, and a net profit of 126 million yuan, a slight increase of 0.08% [5]. Research and Development - As of the end of 2024, the number of R&D personnel reached 492, accounting for 22.15% of the total workforce, reflecting a year-on-year growth of 4.9% [3][10]. - The company has maintained R&D expenditure at over 10% of revenue for several years, with R&D expenses in Q1 2025 reaching 63.11 million yuan, a year-on-year increase of 54.19% [11]. - JiuDian Pharmaceutical has a robust R&D team of over 400 members, primarily composed of PhD and master's degree holders, focusing on innovative drug development [9][10]. Product Portfolio - The company specializes in the research, production, and sales of pharmaceutical products, including drug formulations, raw materials, and plant extracts, with key products in various therapeutic areas [4]. - JiuDian Pharmaceutical has a diverse product range, including anti-inflammatory, anti-infection, and cardiovascular drugs, with leading products such as Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets [4]. Shareholder Activity - The actual controller and chairman, Zhu Zhihong, has shown confidence in the company's future by increasing his shareholding, acquiring shares worth approximately 18.89 million yuan [12][13]. - The company has also been actively repurchasing shares, with a total of 6.1808 million shares repurchased, accounting for 1.24% of the total share capital [14]. Dividend Policy - Since its listing, JiuDian Pharmaceutical has distributed dividends nine times, with a total payout of 463 million yuan, including over 100 million yuan in dividends for the past two consecutive years [15].

Core Viewpoint - The company, Jiutian Pharmaceutical, anticipates a revenue growth of 10% to 20% for the fiscal year 2025, along with a similar increase in net profit excluding non-recurring items [1] Summary by Category - **Revenue Forecast**: Jiutian Pharmaceutical expects its operating revenue for 2025 to grow by 10% to 20% year-on-year [1] - **Net Profit Forecast**: The company projects a year-on-year increase of 10% to 20% in net profit after excluding non-recurring items for the same period [1]

Group 1 - The core viewpoint of the article is that Jiutian Pharmaceutical (300705) is optimistic about the market prospects for its anti-inflammatory and analgesic plaster, primarily focusing on OTC channels for sales [1] - The company plans to enhance sales of the anti-inflammatory and analgesic plaster and other new products by concentrating on OTC channels, sharing sales resources, and enriching its product matrix [1] - The aging population is expected to lead to a continuous increase in the chronic pain patient demographic, which will further drive the market demand for transdermal drug delivery products [1]